An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors

Recruiting now · Phase 1/Phase 2

Conditions studied: Advanced Malignant Solid Tumor

In brief

This is an early phase trial designed to evaluate the safety, tolerability, and preliminary antitumor activity of RPTR-1-201 in adults with advanced solid tumors. The trial includes dose escalation and dose expansion parts and will evaluate RPTR-1-201 as monotherapy and in combination with an anti-PD-1 monoclonal antibody.

Key facts

Study ID
NCT07293754
Run by
Repertoire Immune Medicines
People needed
150
Starts
2025-12-12
Expected to finish
2029-04-15
Last updated by the study team
2026-02-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.